Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $21.39 USD
Change Today -1.32 / -5.81%
Volume 754.5K
SCMP On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

sucampo pharmaceuticals-cl a (SCMP) Snapshot

Open
$22.67
Previous Close
$22.71
Day High
$22.96
Day Low
$21.31
52 Week High
07/20/15 - $25.00
52 Week Low
07/31/14 - $5.80
Market Cap
965.9M
Average Volume 10 Days
1.0M
EPS TTM
$0.50
Shares Outstanding
45.2M
EX-Date
--
P/E TM
42.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for SUCAMPO PHARMACEUTICALS-CL A (SCMP)

sucampo pharmaceuticals-cl a (SCMP) Related Businessweek News

No Related Businessweek News Found

sucampo pharmaceuticals-cl a (SCMP) Details

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs in the Americas, Europe, and Asia. It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders, as well as other therapeutic applications of drug technologies. The company’s product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Bethesda, Maryland.

80 Employees
Last Reported Date: 03/9/15
Founded in 1996

sucampo pharmaceuticals-cl a (SCMP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $440.2K
Co-Founder, Chairman Emeritus and Scientific ...
Total Annual Compensation: $144.5K
Chief Financial Officer
Total Annual Compensation: $286.0K
Senior Vice President of Sales & Marketing an...
Total Annual Compensation: $242.8K
Chief Medical Officer
Total Annual Compensation: $242.8K
Compensation as of Fiscal Year 2014.

sucampo pharmaceuticals-cl a (SCMP) Key Developments

Sucampo Pharmaceuticals Reaffirms Earnings Guidance for Full Year 2015

Sucampo Pharmaceuticals reaffirmed earnings guidance for full year 2015. For the year, the company said that it continues to see earnings per share of $0.55 - $0.65.

Sucampo Pharmaceuticals, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 02:00 PM

Sucampo Pharmaceuticals, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 02:00 PM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Peter S. Greenleaf, Chief Executive Officer and Director.

Sucampo Pharmaceuticals, Inc. Accepts Investigational New Drug Application for A Pivotal Study of AMITIZA

Sucampo Pharmaceuticals, Inc. announced that the China Food and Drug Administration (CFDA) has accepted an Investigational New Drug (IND) application for a pivotal study of AMITIZA in patients with chronic idiopathic constipation. Harbin Gloria Pharmaceuticals Co. Ltd. (Gloria) will design and conduct the study under the terms of its exclusive license, development, commercialization and supply agreement with Sucampo for AMITIZA in China. In connection with the IND acceptance, Sucampo will receive $500,000 from Gloria, which is the second tranche of the $1.5 million upfront payment agreed to as part of the licensing agreement.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCMP:US $21.39 USD -1.32

SCMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ironwood Pharmaceuticals Inc $10.40 USD -0.13
Momenta Pharmaceuticals Inc $21.96 USD -0.47
Pernix Therapeutics Holdings Inc $4.85 USD -0.32
Progenics Pharmaceuticals Inc $8.43 USD -0.99
Sagent Pharmaceuticals Inc $25.41 USD -0.06
View Industry Companies
 

Industry Analysis

SCMP

Industry Average

Valuation SCMP Industry Range
Price/Earnings 54.3x
Price/Sales 8.4x
Price/Book 10.8x
Price/Cash Flow 54.6x
TEV/Sales 7.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUCAMPO PHARMACEUTICALS-CL A, please visit www.sucampo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.